ENXTPA:ALQGC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Quantum Genomics Société Anonyme

Market Cap

€95.3m

Last Updated

2021/06/24 18:42 UTC

Data Sources

Company Financials +

Executive Summary

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. More Details


Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has Quantum Genomics Société Anonyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALQGC is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ALQGC's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-3.2%

ALQGC

-3.1%

FR Biotechs

-0.8%

FR Market


1 Year Return

18.1%

ALQGC

21.9%

FR Biotechs

36.3%

FR Market

Return vs Industry: ALQGC underperformed the French Biotechs industry which returned 21.1% over the past year.

Return vs Market: ALQGC underperformed the French Market which returned 36.1% over the past year.


Shareholder returns

ALQGCIndustryMarket
7 Day-3.2%-3.1%-0.8%
30 Day-8.6%-3.5%3.6%
90 Day-22.5%-8.1%11.2%
1 Year18.1%18.1%21.9%21.9%40.6%36.3%
3 Year84.0%84.0%-12.8%-12.9%37.4%25.8%
5 Year-30.7%-30.7%-47.0%-47.0%90.4%62.6%

Long-Term Price Volatility Vs. Market

How volatile is Quantum Genomics Société Anonyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Quantum Genomics Société Anonyme undervalued compared to its fair value and its price relative to the market?

3.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALQGC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALQGC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALQGC is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: ALQGC is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALQGC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALQGC is good value based on its PB Ratio (3.5x) compared to the FR Biotechs industry average (4.1x).


Future Growth

How is Quantum Genomics Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

58.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALQGC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).

Earnings vs Market: ALQGC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALQGC's is expected to become profitable in the next 3 years.

Revenue vs Market: ALQGC's revenue (34.7% per year) is forecast to grow faster than the French market (7% per year).

High Growth Revenue: ALQGC's revenue (34.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALQGC is forecast to be unprofitable in 3 years.


Past Performance

How has Quantum Genomics Société Anonyme performed over the past 5 years?

-17.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALQGC is currently unprofitable.

Growing Profit Margin: ALQGC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALQGC is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.

Accelerating Growth: Unable to compare ALQGC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALQGC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).


Return on Equity

High ROE: ALQGC has a negative Return on Equity (-42.52%), as it is currently unprofitable.


Financial Health

How is Quantum Genomics Société Anonyme's financial position?


Financial Position Analysis

Short Term Liabilities: ALQGC's short term assets (€33.5M) exceed its short term liabilities (€7.1M).

Long Term Liabilities: ALQGC's short term assets (€33.5M) exceed its long term liabilities (€731.8K).


Debt to Equity History and Analysis

Debt Level: ALQGC's debt to equity ratio (0.01%) is considered satisfactory.

Reducing Debt: ALQGC's debt to equity ratio has reduced from 0.01% to 0.01% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALQGC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALQGC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23% each year


Dividend

What is Quantum Genomics Société Anonyme current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALQGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALQGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALQGC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALQGC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALQGC's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Jean-Philippe Milon (60 yo)

3.17yrs

Tenure

Dr. Jean-Philippe Milon, PhD., has been the Chief Executive Officer at Quantum Genomics Société Anonyme since April 06, 2018, and serves as its MD, and has also been its Director since June 17, 2019. Dr. M...


Leadership Team

Experienced Management: ALQGC's management team is considered experienced (3.2 years average tenure).


Board Members

Experienced Board: ALQGC's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.7%.


Top Shareholders

Company Information

Quantum Genomics Société Anonyme's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quantum Genomics Société Anonyme
  • Ticker: ALQGC
  • Exchange: ENXTPA
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €95.254m
  • Shares outstanding: 26.89m
  • Website: https://www.quantum-genomics.com

Number of Employees


Location

  • Quantum Genomics Société Anonyme
  • 33, rue Marbeuf
  • Paris
  • Ile-de-France
  • 75008
  • France

Listings


Biography

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to tr...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/24 18:42
End of Day Share Price2021/06/24 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.